Spinal cord injury (SCI) affects an estimated three million persons worldwide, with ∼180,000 new cases reported each year leading to severe motor and sensory functional impairments that affect personal and social behaviors. To date, no effective treatment has been made available to promote neurological recovery after SCI. Deficits in motor function is the most visible consequence of SCI; however, other secondary complications produce a significant impact on the welfare of patients with SCI. Spasticity is a neurological impairment that affects the control of muscle tone as a consequence of an insult, trauma, or injury to the central nervous system, such as SCI. The management of spasticity can be achieved through the combination of both nonpharmacological and pharmacological approaches. Baclofen is the most effective drug for spasticity treatment, and it can be administered both orally and intrathecally, depending on spasticity location and severity. Interestingly, recent data are revealing that baclofen can also play a role in neuroprotection after SCI. This new function of baclofen in the SCI scope is promising for the prospect of developing new pharmacological strategies to promote functional recovery in patients with SCI.
Get full access to this article
View all access options for this article.
References
1.
MaynardF.M., KarunasR.S., and WaringW.P. (1990). Epidemiology of spasticity following traumatic spinal cord injury. Arch. Phys. Med. Rehabil. 71, 566–569.
2.
LanceJ.W. Pathophysiology of spasticity and clinical experience with baclofen. In: Lance, J.W., Feldman, R.G., Young, R..R., and Koella, W.P., eds. Spasticity: Disordered Motor Control. Chicago: Year Book Medical Publishers; 1980, pp. 185–204.
3.
PandyanA.D., GregoricM., BarnesM.P., WoodD., Van WijckF., BurridgeJ., HermensH., and JohnsonG.R. (2005). Spasticity: clinical perceptions, neurological realities and meaningful measurement. Disabil. Rehabil. 27, 2–6.
4.
KhederA., and NairK. (2012). Spasticity: pathophysiology, evaluation and management. Pract. Neurol. 12, 289–298.
5.
NickollsP., CollinsD.F., GormanR.B., BurkeD., and GandeviaS.C. (2004). Forces consistent with plateau-like behaviour of spinal neurons evoked in patients with spinal cord injuries. Brain, 127, 660–670.
6.
StevensonV.L., and PlayfordD. (2012). Neurological rehabilitation and the management of spasticity. Medicine, 40, 513–517.
7.
NortonJ.A., WoodD.E., MarsdenJ.F., and DayB.L. (2003). Spinally generated electromyographic oscillations and spasms in a low-thoracic complete paraplegic. Mov. Disord. 18, 101–106.
MurrayK.C., StephensM.J., RankM., D'AmicoJ., GorassiniM.A., and BennettD.J. (2011). Polysynaptic excitatory postsynaptic potentials that trigger spasms after spinal cord injury in rats are inhibited by 5-HT 1B and 5-HT 1F receptors. J. Neurophysiol. 106, 925–943.
13.
RankM.M., MurrayK.C., StephensM.J., D'AmicoJ., GorassiniM.A., and BennettD.J. (2011). Adrenergic receptors modulate motoneuron excitability, sensory synaptic transmission and muscle spasms after chronic spinal cord injury. J. Neurophysiol. 105, 410–422.
14.
ZewdieE., RoyF., YangJ., and GorassiniM. (2011). Increases in the excitability of spinal inhibitory pathways from intensive locomotor training after incomplete spinal cord injury. J. Clin. Neurophysiol. 122, S177–S178.
15.
AdamsM.M., and HicksA.L. (2005). Spasticity after spinal cord injury. Spinal Cord, 43, 577–586.
16.
RodeG., MaupasE., LuauteJ., Courtois-JacquinS., and BoissonD. (2003). Medical treatment of spasticity. Neuro-chirurgie, 49, 247—255.
17.
D'AmicoJ.M., CondliffeE.G, MartinsK.J., BennettD.J., and GorassiniM.A. (2014). Recovery of neuronal and network excitability after spinal cord injury and implications for spasticity. Front. Integr. Neurosci. 8, 36.
18.
BirnsJ., and IraniT.S. (1998). Management of spasticity. Age Ageing, 27, 239–245.
19.
MarciniakC., RaderL., and GagnonC. (2008). The use of botulinum toxin for spasticity after spinal cord injury. Am. J. Phys. Med. Rehabil. 87, 312–317.
DuncanG.W., ShahaniB.T., and YoungR.R. (1976). An evaluation of baclofen treatment for certain symptoms in patients with spinal cord lesions: a double-blind, cross-over study. Neurology, 26, 441–446.
22.
HudgsonP., and WeightmanD. (1971). Baclofen in the treatment of spasticity. Br. Med. J. 4, 15–17.
23.
PennR., and KroinJ. (1985). Continuous intrathecal baclofen for severe spasticity. Lancet, 2, 125–127.
24.
AlbrightA.L. (1996). Baclofen in the treatment of cerebral palsy. J. Child Neurol. 11, 77–83.
25.
GraciesJ.M., NanceP., ElovicE., McGuireJ., and SimpsonD.M. (1997). Traditional pharmacological treatments for spasticity. Part II: general and regional treatments. Muscle Nerve Suppl, 6, S92–S120.
Kruidering-HallM., and CampbellL. Sketelal muscle relaxants. In: Katzung BG, ed. Basic and Clinical Pharmacology. 14th ed. New York: Lange. 2018, pp. 474–491.
30.
SieghartW., FuchsK., TretterV., EbertV., JechlingerM., HogerH, and AdamikerD. (1999). Structure and subunit composition of GABA (A) receptors. Neurochem. Int. 34, 379–385.
31.
DutheyB., CaudronS., PerroyJ., BettlerB., FagniL., PinJ.P., and PrezeauL. (2002). A single subunit (GB2) is required for G-protein activation by the heterodimeric GABA(B) receptor. J. Biol. Chem. 277, 3236–3241.
32.
KniazeffJ., GalvezT., LabesseG., and PinJ.P. (2002). No ligand binding in the GB2 subunit of the GABA(B) receptor is required for activation and allosteric interaction between the subunits. J. Neurosci. 22, 7352–7361.
33.
MottD. (2015). The metabotropic GABA. Cell. Mol. Neurophysiol. 11, 245–267.
34.
BenesF.M., and BerrettaS. (2001). GABAergic interneurons: Implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology, 25, 1–27.
35.
WongC., BottiglieriT., and SneadO.C. (2003). GABA, gamma-hydroxybutyric acid, and neurological disease. Ann. Neurol. 54, Suppl. 6, S3–S12.
36.
KeberleH., and FaigleJ.W. (1968). Pharmaceutical preparations containing Y-amino-B(3:4-chlorophenyl)-Butyric acid. United States Pat Off, 28, 131–134.
37.
BrogdenR.N., SpeightT.M., and AveryG.S. (1974). Baclofen: a preliminary report of its pharmacological properties and therapeutic efficacy in spasticity. Drugs, 8, 1–14.
38.
GorsaneM.A., KebirO., HacheG., lechaL., AubinH.J., RaynaudM., and BenyaminaA. (2012). Is baclofen a revolutionary medication in alcohol addiction management?. Review and recent updates. Subst. Abus. 33, 336–349.
39.
FalchE., HedegaardA., NielsenL., JensenB.R., HjedsH., and Krogsgaard-LarsenP. (1986), Comparative stereostructure-activity studies on GABAA and GABAB receptor sites and GABA uptake using rat brain membrane preparations. J. Neurochem. 47, 898–903.
40.
HillD.R., and BoweryN.G. (1981). 3H-baclofen and 3H-GABA bind to bicuculline-insensitive GABA B sites in rat brain. Nature, 290, 149–152.
41.
MisgeldU., BijakM., and JarolimekW. (1995). A physiological role for GABAB receptors and the effects of baclofen in the mammalian central nervous system. Prog. Neurobiol. 46, 423–462.
42.
RagoL.K., and ZarkovskyA.M. (1983). Bicuculline insensitive effects of baclofen. Arch. Pharmacol. 322, 166–169.
CousinsM.S., RobertsD.C., and de WitH. (2002). GABA(B) receptor agonists for the treatment of drug addiction: a review of recent findings. Drug Alcohol Depend. 65, 209–220.
45.
BroftA..I, SpanosA., CorwinR., MayerL., SteinglassJ., DevlinM.J., AttiaE., and WalshB.T. (2007). Baclofen for binge eating: an open-label trial. Int. J. Eat. Disord. 40, 687–691.
46.
ArimaH., and OisoY. (2010). Positive effect of baclofen on body weight reduction in obese subjects: a pilot study. Intern. Med. 49, 2043–2047.
47.
KnutssonE., LindblomU., and MårtenssonA. (1974). Plasma and cerebrospinal fluid levels of baclofen (Lioresal) at optimal therapeutic responses in spastic paresis. J. Neurol Sci. 23, 473–484.
48.
GianinoJ.M., YorkM.M., PaiceJ.A., and ShottS. (1998). Quality of life: effect of reduced spasticity from intrathecal baclofen. J. Neurosci. Nurs. 30, 47–54.
49.
KirshblumS. (1999). Treatment alternatives for spinal cord injury related spasticity. J. Spinal Cord Med. 22, 199–217.
50.
LoubserP.G., NarayanR.K., SandinK.J., DonovanW.H., and RussellK.D. (1991). Continuous infusion of intrathecal baclofen: long-term effects on spasticity in spinal cord injury. Paraplegia, 29, 48–64.
51.
MüllerH., ZierskiJ., DralleD., KraußD., and MutschlerE. Pharmacokinetics of intrathecal baclofen. In: Müller, H., Zierski, J., Penn, R.D., eds. Local-spinal Therapy of Spasticity. Berlin, Heidelberg: Springer. 1988, pp. 223–226.
52.
PennR.D. (1992). Intrathecal baclofen for spasticity of spinal origin: seven years of experience. J. Neurosurg. 77, 236–240.
53.
OrdiaJ.I., FischerE., AdamskiE., and SpatzE.L. (1996). Chronic intrathecal delivery of baclofen by a programmable pump for the treatment of severe spasticity. J. Neurosurg. 85, 452–457.
54.
McCormickZ.L., ChuS.K., BinlerD., NeudorfD., MathurS.N., LeeJ., and MarciniakC. (2016). Intrathecal versus oral baclofen: a matched cohort study of spasticity, pain, sleep, fatigue, and quality of life. PM R, 8, 553–562.
55.
BurchielK.J., and HsuF.P. (2001). Pain and spasticity after spinal cord injury: mechanisms and treatment. Spine, 26, Suppl. 24, S146–S160.
56.
ErtzgaardP., CampoC., and CalabreseA. (2017). Efficacy and safety of oral baclofen in the management of spasticity: a rationale for intrathecal baclofen. J. Rehabil. Med. 49, 193–203.
57.
OchsG., NaumannC., DimitrijevicM., and SindouM. (1999). Intrathecal baclofen therapy for spinal origin spasticity: spinal cord injury, spinal cord disease, and multiple sclerosis. Neuromodulation, 2, 108–119.
58.
CoffeyR.J., CahillD., SteersW., ParkT.S., OrdiaJ. M, eythalerJ., HermanR., ShetterA.G., LevyR., GillB., SmithR., WilbergerJ., LoeserJ.D., ChabalC., FelerC., RobertsonJ.T., PennR.D., ClarkeA., BurchielJ, and LeibrockL.G. (1993). Intrathecal baclofen for intractable spasticity of spinal origin: results of a long-term multicenter study. J. Neurosurg. 78, 226–232.
59.
RidleyB. (2006). Response of intrathecal baclofen resistance to dose reduction. Neurology, 67, 1495–1496.
60.
HeetlaH.W., StaalM.J., ProostJ.H., and van LaarT. (2014). Clinical relevance of pharmacological and physiological data in intrathecal baclofen therapy. Arch. Phys. Med. Rehabil. 95, 2199–2206.
61.
AbeT., TaniguchiW., NishioN., NakatsukaT., YoshidaM., and YamadaH. (2019). Molecular mechanisms of the antispasticity effects of baclofen on spinal ventral horn neurons. Neuroreport, 30, 19–25.
62.
DavidoffR.A. (1985). Antispasticity drugs: mechanisms of action. Ann. Neurol. 17, 107-116.
63.
PadgettC.L., and SlesingerP.A. (2010). GABAB receptor coupling to G-proteins and ion channels. Adv. Pharmacol. 58, 123–147.
64.
EnnaSJ. The GABA receptors. In: Enna, S.J., and Möhler, H., eds. The GABA Receptors. 3rd ed. Totowa, NJ: Humana Press Inc. 2006, pp. 1–21.
65.
YangK., WangD., and LiY.Q. (2001). Distribution and depression of the GABA(B) receptor in the spinal dorsal horn of adult rat. Brain Res. Bull. 55, 479–485.
66.
BoweryN., HillD., HudsonA., DobleA., MiddlemissD.N., ShawJ., and TurnbullM. (1980). (-) Baclofen decreases neurotransmitter release in the mammalian CNS by an action at a novel GABA receptor. Nature, 283, 92–94.
67.
CurtisDR, GyntherBD, LaceyG, BeattieDT. Baclofen: Reduction of presynaptic calcium influx in the cat spinal cord in vivo. Exp Brain Res 1997;113:520–533.
68.
DutarP., and NicollR.A. (1988). A physiological role of GABAB receptors in the central nervous system. Nature, 332, 156–158.
69.
FoxS., KrnjevićK., MorrisM.E., PuilE., and WermanR. (1978). Action of baclofen on mammalian synaptic transmission. Neuroscience, 3, 495–515.
70.
JarolimekW., BäurleJ., and MisgeldU. (1998). Pore mutation in a G-protein-gated inwardly rectifying K+ channel subunit causes loss of K+-dependent inhibition in weaver hippocampus. J. Neurosci. 18, 4001–4007.
71.
LuscherC., JanL., StoffelM., MalenkaR., and NicollR.A. (1997). G protein-coupled inwardly rectifying K+ Channels (GIRKs) mediate postsynaptic but not presynaptic transmitter actions in hippocampal neurons. Neuron, 19, 687–695.
72.
NicollR.A., MalenkaR.C., and KauerJ.A. (1990). Functional comparison of neurotransmitter receptor subtypes in mammalian central nervous system. Physiol. Rev. 70, 513–565.
73.
SodicksonD.L., and BeanB.P. (1996). GABAB receptor-activated inwardly rectifying potassium current in dissociated hippocampal CA3 neurons. J. Neurosci. 16, 6374–6385.
74.
FedermanA., ConklinB., SchraderK., ReedR., and BourneH. (1992). Hormonal stimulation of adenylyl cyclase through Gi-protein BY subunits. Nature, 356, 159–161.
75.
RobichonA., TinetteS., CourtialC., and PelletierF. (2004). Simultaneous stimulation of GABA and beta adrenergic receptors stabilizes isotypes of activated adenylyl cyclase heterocomplex. BMC Cell Biol. 5, 25.
76.
KarbonE.W., DumanR.S., and EnnaS.J. (1984). GABAB receptors and norepinephrine-stimulated cAMP production in rat brain cortex. Brain Res. 306, 327–332.
77.
BensmailD., SalvaM.A., RocheN., BenyahiaS., BohicS., DenysP., BusselB., andLofaso. (2006). Effect of intrathecal baclofen on sleep and respiratory function in patients with spasticity. Neurology, 67, 1432–1436.
78.
FinnimoreA.J., RoebuckM., SajikovD., and McEvoyR.D. (1995). The effects of the GABA agonist, baclofen, on sleep and breathing. Eur. Respir. J. 8, 230–234.
79.
JiangS.D., DaiL.Y., and JiangL.S. (2006). Osteoporosis after spinal cord injury. Osteoporos. Int. 17, 180–192.
80.
JohnsonR.L., GerhartK.A., McCrayJ., MenconiJ.C., and WhiteneckG.G. (1998). Secondary conditions following spinal cord injury in a population-based sample. Spinal Cord, 36, 45–50.
81.
KarthikeyanV.S., SenthilkumaranK., EaswaranB., and RajbhaskarR. (2015). Intestinal pseudo-obstruction following oral baclofen: an unusual complication. J. Pharmacol. Pharmacother. 6, 169–171.
82.
KoflerM., MatzakH., and SaltuariL. (2002). The impact of intrathecal baclofen on gastrointestinal function. Brain Inj. 16, 825–836.
83.
PennR., and KroinJ. (1987). Long-term intrathecal baclofen infusion for treatment of spasticity. J. Neurosurg. 66, 181–185.
84.
SezerN., AkkuşS., nd UğurluF.G. (2015). Chronic complications of spinal cord injury. World J. Orthop. 6, 24–33.
85.
SweisR., and BillerJ. (2017). Systemic complications of spinal cord injury. Curr. Neurol. Neurosci. Rep. 17, 8.
86.
DijkersM., BryceT., and ZancaJ. (2009). Prevalence of chronic pain after traumatic spinal cord injury: a systematic review. J. Rehabil. Res. Dev. 46, 13–29.
87.
NepomucenoC., FineP.R., RichardsJ.S., GowensH., StoverS.L., RantanuabolU., and HoustonR. (1979). Pain in patients with spinal cord injury. Arch. Phys. Med. Rehabil. 60, 605–609.
88.
HwangJ.H., and YakshT.L. (1997). The effect of spinal GABA receptor agonists on tactile allodynia in a surgically-induced neuropathic pain model in the rat. Pain, 70, 15–22.
89.
WilsonP.R., and YakshT.L. (1978). Baclofen is antinociceptive in the spinal intrathecal space of animals. Eur. J. Pharmacol. 51, 323–330.
90.
KumruH., Benito-PenalvaJ., KoflerM., and VidalJ. (2018). Analgesic effect of intrathecal baclofen bolus on neuropathic pain in spinal cord injury patients. Brain Res. Bull. 140, 205–211.
91.
LoubserP., and AkmanN. (1996). Effects of intrathecal baclofen on chronic spinal cord injury pain. J. Pain Symptom Manage. 12, 241–247.
92.
GhoseK., HolmesK.M., and MatthewsonK. (1980). Complications of baclofen overdosage. Postgrad. Med. J. 56, 865–867.
93.
GentiliniG., Franchi-MicheliS., PantaloneD., CortesiniC., and ZillettiL. (1992). GABAB receptor-mediated mechanisms in human intestine in vitro. Eur. J. Pharmacol. 217, 9–14.
94.
KwonB.K., TetzlaffW., GrauerJ.N., BeinerJ., and VaccaroA.R. (2004). Pathophysiology and pharmacologic treatment of acute spinal cord injury. Spine J. 4, 451–464.
95.
SilvaN.A., SousaN., ReisR.L., and SalgadoA.J. (2014). From basics to clinical: a comprehensive review on spinal cord injury. Prog. Neurobiol. 114, 25–57.
96.
KakulasB.A. (1999). The applied neuropathology of human spinal cord injury. Spinal Cord, 37, 79–88.
97.
BlightA.R. (1983). Cellular morphology of chronic spinal cord injury in the cat: Analysis of myelinated axons by line-sampling. Neuroscience, 10, 521–543.
98.
EidelbergE., StraehleyD., ErspamerR., and WatkinsC. (1977). Relationship between residual hindlimb-assisted locomotion and surviving axons after incomplete spinal cord injuries. Exp. Neurol. 56, 312–322.
99.
FehlingsM.G., and TatorC.H. (1995). The relationships among the severity of spinal cord injury, residual neurological function, axon counts, and counts of retrogradely labeled neurons after experimental spinal cord injury. Exp. Neurol. 132, 220–228.
100.
LalS., ShuaibA., and IjazS. (1995). Baclofen is cytoprotective to cerebral ischemia in gerbils. Neurochem. Res. 20, 115–119.
101.
Jackson-FriedmanC., LydenP.D., NunezS., JinA., and ZweiflerR. (1997). High dose baclofen is neuroprotective but also causes intracerebral hemorrhage: a quantal bioassay study using the intraluminal suture occlusion method. Exp. Neurol. 147, 346–352.
102.
RosenbaumD.M., GrottaJ.C., PettigrewL.C., OstrowP., StrongR., RhoadesH., PiconeC.M., and GrottaA.T. (1990). Baclofen does not protect against cerebral ischemia in rats. Stroke, 21, 138–140.
103.
LuytK., SladeT.P., DorwardJ.J., DurantC.F., WuY., ShigemotoR., MundellS.J., VaradiA., and MolnarE. (2007). Developing oligodendrocytes express functional GABA(B) receptors that stimulate cell proliferation and migration. J. Neurochem. 100, 822–840.
104.
MagnaghiV., BallabioM., CavarrettaI.T., FroestlW., LambertJ.J., ZucciI., and MelcangiR.C. (2004). GABAB receptors in Schwann cells influence proliferation and myelin protein expression. Eur. J. Neurosci. 19, 2641–2649.
105.
Fernández-LópezB., Valle-MarotoS.M., Barreiro-IglesiasA., and RodicioM.C. (2014). Neuronal release and successful astrocyte uptake of aminoacidergic neurotransmitters after spinal cord injury in lampreys. Glia, 62, 1254–1269.
106.
Fernández-LópezB., Barreiro-IglesiasA., and RodicioM.C. (2016). Anatomical recovery of the spinal glutamatergic system following a complete spinal cord injury in lampreys. Sci. Rep. 6, 37786.
107.
LiuD., XuG.Y., PanE., and McAdooD.J. (1999). Neurotoxicity of glutamate at the concentration released upon spinal cord injury. Neuroscience, 93, 1383–1389.
108.
ModyI., and MacDonaldJ.F. (1995). NMDA receptor-dependent excitotoxicity: the role of intracellular Ca2+ release. Trends Pharmacol. Sci. 16, 356–359.
109.
Romaus-SanjurjoD., Valle-MarotoS.M., Barreiro-IglesiasA., Fernández-LópezB., and RodicioM.C. (2018). Anatomical recovery of the GABAergic system after a complete spinal cord injury in lampreys. Neuropharmacology, 131, 389–402.
110.
Sobrido-CameánD., and Barreiro-IglesiasA. (2018). Role of caspase-8 and fas in cell death after spinal cord injury. Front. Mol. Neurosci. 11, 101.
111.
WuY.N., ShenK.Z., and JohnsonS.W. (1999). Presynaptic inhibition preferentially reduces the NMDA receptor-mediated component of transmission in rat midbrain dopamine neurons. Br. J. Pharmacol. 127, 1422–1430.
112.
Romaus-SanjurjoD., Ledo-GarcíaR., Fernández-LópezB., HanslikK., MorganJ.R., Barreiro-IglesiasA., and RodicioM.C.\. (2018). GABA promotes survival and axonal regeneration in identifiable descending neurons after spinal cord injury in larval lampreys. Cell Death Dis. 9, 663.
113.
Romaus-SanjurjoD., RodicioM.C., and Barreiro-IglesiasA. (2019). Gamma-aminobutyric acid (GABA) promotes recovery from spinal cord injury in lampreys: role of GABA receptors and perspective on the translation to mammals. Neural Regen. Res. 14, 1695–1696.
114.
Sobrido-CameánD., RobledoD., Romaus-SanjurjoD., Perez-CedronV., SanchezL., RodicioM.C., and Berriero-IglesiasA. (2020). Inhibition of gamma-secretase promotes axon regeneration after a complete spinal cord injury. Front. Cell Dev. Biol. 8, 173.
115.
AzouviP., ManeM., ThiebautJ.B., DenysP., Remy-NerisO., and BusselB. (1996). Intrathecal baclofen administration for control of severe spinal spasticity: functional improvement and long-term follow-up. Arch. Phys. Med. Rehabil. 77, 35–39.
116.
DarioA., ScamoniC., BonoG., GhezziA., and ZaffaroniM. (2001). Functional improvement in patients with severe spinal spasticity treated with chronic intrathecal baclofen infusion. Funct. Neurol. 16, 311–315.
117.
NormanK.E., PépinA., and BarbeauH. (1998). Effects of drugs on walking after spinal cord injury. Spinal Cord, 36, 699–715.
118.
CraggJ.J., TongB., JutzelerC.R., WarnerF.M., CashmanN., GeislerF, and KramerJ.L. (2019). A longitudinal study of the neurologic safety of acute baclofen use after spinal cord injury. Neurotherapeutics, 16, 858–867.
119.
TheriaultE.R., HuangV., WhiteneckG., DijkersM.P., and HarelN.Y. (2018). Antispasmodic medications may be associated with reduced recovery during inpatient rehabilitation after traumatic spinal cord injury. J. Spinal Cord Med. 41, 63–71.
